TP53 and B-cell chronic lymphocytic leukemia: High-risk genomic abnormalities have an important bearing on the prognosis of CLL, none more so than aberrations of TP53 on chromosome 17 (del([17p] and/or TP53 mutations), which retain prognostic significance in the novel therapy era [3, 28–30].